Key result
Pioglitazone reduces carotid intima-media thickness by ~0.03 mm vs glimepiride in type 2 diabetes.
Why the study?
The role of intact proinsulin and adiponectin in endothelial dysfunction and insulin resistance in type 2 diabetes patients was increasingly recognized but not fully understood.
Does pioglitazone improve metabolic and vascular parameters compared to glimepiride in patients with type 2 diabetes?
RCT (n=173)
randomly assigned
Does pioglitazone improve metabolic and vascular parameters compared to glimepiride in patients with type 2 diabetes?
p-value: p=<0.0001
Pioglitazone improves insulin sensitivity, adiponectin, intact proinsulin, and carotid intima media thickness in type 2 diabetes compared to glimepiride, independent of glycemic control.
The role of intact proinsulin and adiponectin in endothelial dysfunction and insulin resistance has been receiving increasing attention. This study investigates the effect of PPARgamma stimulation or beta-cell stimulation on metabolic and vascular parameters in patients with type 2 diabetes. In our study, 173 type 2 diabetic patients were recruited and randomly assigned to pioglitazone 45 mg or glimepiride 1 - 6 mg treatment. Intima media thickness of the carotid artery, glycemic control, insulin resistance, adiponectin and intact proinsulin levels were assessed at baseline and after six months of treatment. Despite similar improvements in metabolic control (HbA (1c) after 24 weeks: - 0.8 +/- 0.9% [pioglitazone] vs. - 0.6 +/- 0.8% [glimepiride]; mean +/- SD; p < 0.0001, respectively), improvements in intima media thickness (- 0.033 +/- 0.052 mm; p < 0.0001), proinsulin intact (- 5.92 +/- 10.04 pmol/l; p < 0.0001), adiponectin (10.9 +/- 6.3 microg/ml; p < 0.0001) and HOMA score (- 2.21 +/- 3.40; p < 0.0001) were observed by pioglitazone but not glimepiride treatment. Reduction in intima media thickness was correlated with improved insulin sensitivity (r = 0.29; p = 0.0003), and proinsulin intact levels (r = 0.22; p = 0.006), while an inverse correlation was found with adiponectin levels (r = - 0.37; p < 0.0001). Measurement of adiponectin and intact proinsulin enables characterization of the metabolic situation and an estimation of atherosclerotic risk in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Forst et al. (2005) conducted an RCT in Type 2 diabetes (n=173). Pioglitazone vs. Glimepiride 1 - 6 mg was evaluated on Change in intima media thickness (p=<0.0001). Pioglitazone significantly reduced intima media thickness (-0.033 mm; P<0.0001) and improved adiponectin and intact proinsulin levels compared to glimepiride in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: